{'fraction_non_alphanumeric': 0.01818181818181818, 'fraction_numerical': 0.0, 'mean_word_length': 5.232704402515723, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Research progress of receptor targeted hepatic stellate cell in treatment of liver fibrosis].

Liver fibrosis is a major public health problem with high morbidity and mortality rate. Despite noteworthy progress in understanding the mechanisms of liver fibrosis, anti-hepatic fibrosis treatments have partial efficacy. The main reason is failure of transported target drug into the target cells, resulting in insufficient concentration of target drugs, and the side effects caused by non-target cells are large. Activation and proliferation of hepatic stellate cell is a key link in the progression of liver fibrosis. Therefore, one of the main goals of anti-fibrotic therapy is to develop a drug delivery system targeting hepatic stellate cells to efficiently target drugs in active hepatic stellate cells without affecting other organs and other cells in the liver. In this review, we outline a number of receptor-mediated strategies for targeting drug delivery in hepatic stellate cells.